Yes they mentioned that is their focus, but Novartis would be blind to ignore the potential synergy drug combo of Rex and entresco. It looks like Novartis will have a hard time getting across the line with the FDA with Entresco alone when treating CHF. It seems in their best interest to match up with MSB for this indication. Better to both be over the line than neither of them. Not to mention the amount of lives which would have extended lifespans with increased quality of life.
Seems like a no brainer to me..
Where is Novartis?, page-465
-
- There are more pages in this discussion • 1,052 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15990 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 48632 | 3 |
View Market Depth
| Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |